Gary Fujii
Principal investigator.
Biotech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2015First federal award
$8.0MFederal grants as PI17 awards
1Patents grantedLatest Aug 6, 2019
46Papers1,771 citations
Federal awards and patents by year
AwardsPatents
17 awards · $8.0M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| May 6, 2025 | NIH | SBIR Phase II Preclinical Development of a ME-1001, a Synthetic Lung Surfactant | $1000K | MOLECULAR EXPRESS, INC. |
| May 8, 2024 | NIH | SBIR Phase II Preclinical Development of a ME-1001, a Synthetic Lung Surfactant | $1000K | MOLECULAR EXPRESS, INC. |
| Jan 13, 2023 | NIH | SBIR Phase I VesiVax Vaccine Formulation Against Neisseria gonorrhoeae | $300K | MOLECULAR EXPRESS, INC. |
| Aug 1, 2022 | NIH | SBIR Phase II Non-clinical Development of a Synthetic Lung Surfactant for Treatment of NRDS | $113K | MOLECULAR EXPRESS, INC. |
| Jul 28, 2022 | NIH | SBIR Phase II Non-clinical Development of a Synthetic Lung Surfactant for Treatment of NRDS | $67K | MOLECULAR EXPRESS, INC. |
| Jul 8, 2022 | NIH | SBIR Phase I Niclosamide Formulations for the Treatment of Influenza Infections | $298K | MOLECULAR EXPRESS, INC. |
| Jun 6, 2022 | NIH | SBIR Phase II Non-clinical Development of a Synthetic Lung Surfactant for Treatment of NRDS | $1.0M | MOLECULAR EXPRESS, INC. |
| Feb 17, 2022 | NIH | SBIR Phase I VesiVax Vaccine Formulation Against Neisseria gonorrhoeae | $300K | MOLECULAR EXPRESS, INC. |
| Jun 16, 2021 | NIH | SBIR Phase II Non-clinical Development of a Synthetic Lung Surfactant for Treatment of NRDS | $957K | MOLECULAR EXPRESS, INC. |
| Jun 26, 2018 | NIH | SBIR Phase II Development of a Vaccine for the Prevention of Pulmonary Aspergillosis | $497K | MOLECULAR EXPRESS, INC. |
| Jun 28, 2017 | NIH | SBIR Phase II Development of a Vaccine for the Prevention of Pulmonary Aspergillosis | $934K | MOLECULAR EXPRESS, INC. |
| Feb 7, 2017 | NIH | SBIR Phase I VesiVax® Peanut Allergy Immunotherapy | $300K | MOLECULAR EXPRESS, INC. |
| Jul 29, 2016 | NIH | STTR Phase II Pre-clinical Development of a Vaccine for the Treatment of Heroin Addiction | $95K | MOLECULAR EXPRESS, INC. |
| Mar 15, 2016 | NIH | SBIR Phase I Optimization of VesiVax® Lipidated Tucaresol Formulations | $225K | MOLECULAR EXPRESS, INC. |
| Sep 1, 2015 | NIH | STTR Phase II Pre-clinical Development of a Vaccine for the Treatment of Heroin Addiction | $225K | MOLECULAR EXPRESS, INC. |
| Aug 20, 2015 | NIH | STTR Phase I Development of a Gene and Oligonucleotide Delivery System | $323K | MOLECULAR EXPRESS, INC. |
| Jun 10, 2015 | NIH | SBIR Phase I Design and Engineering of Nanoparticulate Universal Vaccines | $290K | MOLECULAR EXPRESS, INC. |
2 patents as inventor
- US 10369229MOLECULAR EXPRESS, INC.Aug 6, 2019
- US MOLECULAR EXPRESS, INC.—
Matched by the first inventor’s name and the patent’s company.
Peer ranks
Federal funding#112
Awards as PI#29
Patents#155
Companies
- MOLECULAR EXPRESS, INC.Linked by awards · Biotech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.